Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Miscellaneous

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) released its earnings results on Monday, November, 5th. The company reported $1.25 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.19 by $0.06. The company earned $2.86 billion during the quarter, compared to the consensus estimate of $2.91 billion. Mylan had a return on equity of 19.39% and a net margin of 4.71%. Mylan's quarterly revenue was down 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.10 EPS. View Mylan's Earnings History.

When is Mylan's next earnings date?

What price target have analysts set for MYL?

17 brokers have issued 1 year price objectives for Mylan's stock. Their forecasts range from $31.00 to $59.00. On average, they expect Mylan's stock price to reach $46.20 in the next year. This suggests a possible upside of 56.1% from the stock's current price. View Analyst Price Targets for Mylan.

What is the consensus analysts' recommendation for Mylan?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

1. According to Zacks Investment Research, "Mylan is also exploring the world of biosimilars, a market that has the potential to grow to $20 billion in 2020. A partnership with Biocon, and collaborations with Momenta and Mabion has helped Mylan develop a portfolio of 20 biosimilar/insulin analog generic products,. The company has launched nearly 475 products year to date across its segments, including a record number of complex generics and biosimilars. In August 2018, Mylan completed an agreement with certain subsidiaries of Novartis to purchase worldwide rights to their global cystic fibrosis products, consisting of the TOBI Podhaler and TOBI solution. This should further broaden the company’s portfolio. However, Mylan proactively discontinued a number of products, while also transferring some to other sites. These have led to a temporary disruption in supply of certain products and reduced volumes in North America Shares have underperformed the industry in the last six months." (1/21/2019)

2. Cantor Fitzgerald analysts commented, "We rate MYL as 12-month price target of $41. We like the company, and there are a lot of potentially positive catalysts coming up. That said, the risk reward is already reflected in the stock’s valuation, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to calculate our 12- month price target of $41." (11/20/2018)

3. Guggenheim analysts commented, "We spoke with two oncologists in different practice settings regarding their potential use of Fulphila. While biosimilar financial incentives will play a role in Fulphila’s adoption, the Onpro device appears entrenched in current clinical practice. For that and other reasons, we believe that it might be more prudent to take a conservative approach to Fulphila’s uptake at the outset. We maintain our BUY rating on shares of Mylan. Consultant Commentary: We spoke with two oncologists on their respective academic and rural private practice settings. The academic consultant saw roughly 100 Neulasta patients per month while the rural oncologist saw ~30 Neulasta patients per month." (6/14/2018)

Has Mylan been receiving favorable news coverage?

News headlines about MYL stock have trended very positive on Monday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Are investors shorting Mylan?

Mylan saw a increase in short interest during the month of December. As of December 14th, there was short interest totalling 8,757,872 shares, an increase of 20.5% from the November 30th total of 7,268,964 shares. Based on an average daily trading volume, of 4,890,774 shares, the short-interest ratio is currently 1.8 days. Currently, 1.7% of the shares of the stock are short sold. View Mylan's Current Options Chain.

Which major investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Nisa Investment Advisors LLC, Advisors Capital Management LLC, Kirr Marbach & Co. LLC IN, Oakbrook Investments LLC, Louisiana State Employees Retirement System, CENTRAL TRUST Co and Gofen & Glossberg LLC IL. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

Which major investors are buying Mylan stock?

MYL stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Cumberland Advisors Inc., State of Alaska Department of Revenue, First Hawaiian Bank and RPG Investment Advisory LLC. View Insider Buying and Selling for Mylan.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $29.59.

How big of a company is Mylan?

Mylan has a market capitalization of $15.26 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

MarketBeat Community Rating for Mylan (NASDAQ MYL)

MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.